Bottom line
Is EPIVX a good fund? The bottom line
EPIVX is the Class A share class of EuroPac International Value Fund, an actively managed international stock mutual fund from First Trust.
It charges 1.71% — about $171 a year on every $10,000 invested, more expensive than 91% of international stock funds we track.
It returned +40.5% over one year, +11.8% a year over five years, +10.8% a year over ten (as of Dec 31, 2024, per its prospectus).
With $197 million in net assets and 45 holdings, its largest position is Novo Nordisk A/S (6.2%) and the top 10 make up 44.8% of the portfolio.
This share class carries a front-end sales charge of up to 4.5%; a no-load class or ETF alternative can avoid it.
What stands out
- 5-year return beat 91% of category peers
What to watch
- Expensive for its category (1.71%)
- Front-end sales load up to 4.5%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What EPIVX invests in
The investment objective of the EuroPac International Value Fund (the Fund) is to seek income and long term capital appreciation.
Under normal market conditions, the Fund will invest at least 80% of its net assets (plus any borrowings for investment purposes) in common stocks of companies located in Europe or the Pacific Rim. The Funds advisor considers a country to be part of Europe if it is included in one of the MSCI European indexes and part of the Pacific Rim if any of its borders touches the Pacific Ocean. The advisor considers a company to be located in Europe or the Pacific Rim if (1) the company is organized under the laws of a country that is part of Europe or the Pacific Rim or has its principal office in a country that is part of Europe or the Pacific Rim; (2) at the time of investment, the company derived a significant portion (i.e., 50% or more) of its total revenues during its most recent completed fiscal year from business activities in Europe or the Pacific Rim; or (3) the companys equity…
From the fund's prospectus (filed Mar 4, 2026).
EPIVX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| EPIVX | +40.5% | +11.8% | +10.8% |
| International Stock median | +25.5% | +6.4% | +7.6% |
Source: Fund prospectus, as of Dec 31, 2024
What EPIVX costs
On a $10,000 investment, EPIVX's 1.71% expense ratio costs about $171 a year. The prospectus estimates $2,379 in total costs over 10 years (assuming 5% annual returns). The median international stock fund charges 0.9%.
EPIVX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Novo Nordisk A/S | 6.21% |
| 2 | British American Tobacco PLC | 6.15% |
| 3 | Evolution AB EVO SS | 5.43% |
| 4 | Dassault Systemes SE DSY FP | 4.69% |
| 5 | IAMGOLD Corp IAG | 4.32% |
| 6 | Agnico Eagle Mines Ltd AEM | 4.05% |
| 7 | Barrick Mining Corp B | 3.72% |
| 8 | Newmont Corp | 3.52% |
| 9 | Kinross Gold Corp KGC | 3.51% |
| 10 | Franco-Nevada Corp FNV | 3.24% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 44.8% of the fund. See all top 25 holdings and asset mix →